U.S. markets open in 6 hours 42 minutes
  • S&P Futures

    4,547.00
    +22.75 (+0.50%)
     
  • Dow Futures

    35,068.00
    +158.00 (+0.45%)
     
  • Nasdaq Futures

    15,137.25
    +103.75 (+0.69%)
     
  • Russell 2000 Futures

    2,069.80
    +10.60 (+0.51%)
     
  • Crude Oil

    86.90
    -0.06 (-0.07%)
     
  • Gold

    1,841.00
    -2.20 (-0.12%)
     
  • Silver

    24.24
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1368
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.85
    +1.06 (+4.65%)
     
  • GBP/USD

    1.3629
    +0.0017 (+0.13%)
     
  • USD/JPY

    114.3980
    +0.0450 (+0.04%)
     
  • BTC-USD

    42,075.09
    +773.80 (+1.87%)
     
  • CMC Crypto 200

    1,000.23
    +5.48 (+0.55%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Aziyo Biologics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SILVER SPRING, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021. Management will host a conference call to review the company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the Aziyo website at www.aziyo.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (800) 708-4539 (US/Canada) or (847) 619-6396 (International) and use the conference ID number 50150586 approximately ten minutes prior to the start time.

About Aziyo Biologics
Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.

Investors:
Leigh Salvo
Gilmartin Group
investors@aziyo.com

Media:
Courtney Guyer
Aziyo Biologics, Inc.
PR@aziyo.com